Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247122 | PMC |
| http://dx.doi.org/10.1038/bjc.1989.327 | DOI Listing |
Publication Analysis
Top Keywords
malignant melanoma
12
metastatic malignant
8
m-2 day
8
treatment metastatic
4
melanoma dacarbazine
4
dacarbazine vindesine
4
vindesine cisplatin
4
cisplatin twenty-seven
4
twenty-seven patients
4
patients disseminated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!